Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY1193397 in Diabetic Foot
NCT03128320Phase 2Completed
- Sponsor
- Bayer
- Start
- May 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of BAY1193397 in diabetic foot disease (DFD) and peripheral artery disease (PAD) (3 arms), sponsored by Bayer. Primary endpoints: Change in resting capillary blood flow velocity, Change in peak CBV during reactive hyperemia and 2 more. Started May 2017; status: completed.
02
Drugs
BAY1193397
03
Conditions
diabetic foot disease (DFD)peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT03128320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03128320.